keyword
https://read.qxmd.com/read/38518853/%C3%AE-asarone-inhibitsautophagy-by-activating-the-pi3k-akt-mtor-pathway-in-a-rat-model-of-depression-in-parkinson-s-disease
#21
JOURNAL ARTICLE
Zhifang Wang, Ping-E Huang, Nanbu Wang, Qinxin Zhang, Jian Kang, Yongqi Fang, Baile Ning, Ling Li
OBJECTIVE: It is unclear whether β-asarone has a good antidepressant effect and what is the main mechanism in Depression in Parkinson's disease (DPD) model rats. METHODS: In this study, DPD model rats were screened from 6-OHDA induced rats by sucrose preference test (SPT) and forced swimming test (FST). DPD model rats were divided into eight groups: model group, pramipexole group, β-asarone low-dose group (β-asarone 7.5 group), β-asarone medium-dose group (β-asarone 15 group), β-asarone high-dose group (β-asarone 30 group), 3-MA group, rapamycin group, and PI3K inhibitor group...
March 20, 2024: Behavioural Brain Research
https://read.qxmd.com/read/38518544/effects-of-supplementary-da-dingfeng-zhu-therapy-on-patients-with-parkinson-s-disease-of-liver-kidney-yin-deficiency-pattern
#22
JOURNAL ARTICLE
Meili Liu, Zhiwei Jia, Tianyu Yao, Guoxian Zhang, Xuejing Wang
BACKGROUND: This study aimed to verify whether the combined use of Da Dingfengzhu and Western medicine in treating Parkinson's disease (PD) can lead to therapeutic efficacy and symptom alleviation, thereby achieving a complementary and synergistic effect. METHODS: In this study, 158 patients were initially enrolled, with 116 eligible patients randomly divided into a control and an observation group. The control group received levodopa/benserazide and pramipexole, while the observation group received Da Dingfengzhu combined with levodopa/benserazide and pramipexole for 12 weeks...
March 18, 2024: Parkinsonism & related Disorders
https://read.qxmd.com/read/38518526/biomarkers-of-physical-and-mental-health-for-prediction-of-parkinson-s-disease-a-population-based-study-from-15-european-countries
#23
JOURNAL ARTICLE
M Azhar Hussain, Rizwan Qaisar, Asima Karim, Firdos Ahmad, Fabio Franzese, Saad M Alsaad, Abeer A Al-Masri, Shaea A Alkahtani
OBJECTIVES: Early diagnosis of Parkinson's disease (PD) is critical for optimal treatment. However, the predictive potential of physical and mental health in PD is poorly characterized. METHODS: We evaluated the potential of multiple demographic, physical, and mental factors in predicting the future onset of PD in older adults aged 50 years or older from 15 European countries. Individual study participants were followed over four waves of the Survey of Health, Ageing, and Retirement in Europe (SHARE) from 2013-2020...
March 21, 2024: Archives of Medical Research
https://read.qxmd.com/read/38517802/reduced-thickness-of-the-retina-in-de-novo-parkinson-s-disease-shows-a-distinct-pattern-different-from-glaucoma
#24
JOURNAL ARTICLE
Asterios Chrysou, Tuomas Heikka, Sygrid van der Zee, Jeffrey M Boertien, Nomdo M Jansonius, Teus van Laar
BACKGROUND: Parkinson's disease (PD) patients experience visual symptoms and retinal degeneration. Studies using optical coherence tomography (OCT) have shown reduced thickness of the retina in PD, also a key characteristic of glaucoma. OBJECTIVE: To identify the presence and pattern of retinal changes in de novo, treatment-naive PD patients compared to healthy controls (HC) and early primary open angle glaucoma (POAG) patients. METHODS: Macular OCT data (10×10 mm) were collected from HC, PD, and early POAG patients, at the University Medical Center Groningen...
March 21, 2024: Journal of Parkinson's Disease
https://read.qxmd.com/read/38517799/treatment-approaches-for-altered-facial-expression-a-systematic-review-in-facioscapulohumeral-muscular-dystrophy-and-other-neurological-diseases
#25
JOURNAL ARTICLE
Nathaniël B Rasing, Willianne A van de Geest-Buit, On Ying A Chan, Karlien Mul, Anke Lanser, Baziel G M van Engelen, Corrie E Erasmus, Agneta H Fischer, Koen J A O Ingels, Bart Post, Ietske Siemann, Jan T Groothuis, Nicol C Voermans
BACKGROUND: Facial weakness is a key feature of facioscapulohumeral muscular dystrophy (FSHD) and may lead to altered facial expression and subsequent psychosocial impairment. There is no cure and supportive treatments focus on optimizing physical fitness and compensation of functional disabilities. OBJECTIVE: We hypothesize that symptomatic treatment options and psychosocial interventions for other neurological diseases with altered facial expression could be applicable to FSHD...
March 21, 2024: Journal of Neuromuscular Diseases
https://read.qxmd.com/read/38517752/structural-mechanisms-for-vmat2-inhibition-by-tetrabenazine
#26
JOURNAL ARTICLE
Michael P Dalton, Mary Hongying Cheng, Ivet Bahar, Jonathan A Coleman
The vesicular monoamine transporter 2 (VMAT2) is a proton-dependent antiporter responsible for loading monoamine neurotransmitters into synaptic vesicles. Dysregulation of VMAT2 can lead to several neuropsychiatric disorders including Parkinson's disease and schizophrenia. Furthermore, drugs such as amphetamine and MDMA are known to act on VMAT2, exemplifying its role in the mechanisms of actions for drugs of abuse. Despite VMAT2's importance, there remains a critical lack of mechanistic understanding, largely driven by a lack of structural information...
March 22, 2024: ELife
https://read.qxmd.com/read/38515787/research-progress-on-ferroptosis-in-the-pathogenesis-and-treatment-of-neurodegenerative-diseases
#27
REVIEW
Lijuan Wang, Xiansong Fang, Baodian Ling, Fangsheng Wang, Yu Xia, Wenjuan Zhang, Tianyu Zhong, Xiaoling Wang
Globally, millions of individuals are impacted by neurodegenerative disorders including Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and Alzheimer's disease (AD). Although a great deal of energy and financial resources have been invested in disease-related research, breakthroughs in therapeutic approaches remain elusive. The breakdown of cells usually happens together with the onset of neurodegenerative diseases. However, the mechanism that triggers neuronal loss is unknown...
2024: Frontiers in Cellular Neuroscience
https://read.qxmd.com/read/38515703/dose-response-relationship-of-levodopa-with-dyskinesia-in-parkinson-s-disease-a-systematic-review-and-meta-analysis
#28
REVIEW
Taozhi He, Dai Wang, Xinyu Zhang, Jiawen Liu, Shiyu Fang, Zhe Zhang, Hongjie Liu
Despite existing evidence linking dyskinesia to levodopa, the primary treatment for Parkinson's, the dose-response relationship and risk factors remain uncertain. In this study, the risk for dyskinesia in patients with Parkinson's disease receiving levodopa was evaluated via meta-analysis and meta-regression approaches to examine dyskinesia risk factors more reliably and improve treatment strategies and patient care. The PubMed and Embase databases were searched to identify randomized controlled trials comparing levodopa with other anti-Parkinson's drugs published in English before June 31, 2023...
March 30, 2024: Heliyon
https://read.qxmd.com/read/38515319/antagonism-of-metabotropic-glutamate-receptor-type-5-prevents-levodopa-induced-dyskinesia-development-in-a-male-rat-model-of-parkinson-s-disease-electrophysiological-evidence
#29
JOURNAL ARTICLE
Hikaru Kamo, Hirokazu Iwamuro, Ryota Nakamura, Shuko Nojiri, Ayami Okuzumi, Takashi Ogawa, Asuka Nakajima, Nobutaka Hattori, Yasushi Shimo
Levodopa-induced dyskinesia (LID) is a common complication in patients with advanced Parkinson's disease (PD) undergoing treatment with levodopa. Glutamate receptor antagonists can suppress LID; however, the underlying mechanisms remain unclear. Here, we aimed to evaluate the effect of 3-((2-methyl-1,3-thiazol-4-yl)ethynyl)pyridine (MTEP), a metabotropic glutamate receptor 5 (mGluR5) antagonist, on dyskinesia. We recorded the neuronal activity of the entopeduncular nucleus and examined responses to cortical electric stimulation in the control group (n = 6) and three groups of rats (male PD model)...
March 2024: Journal of Neuroscience Research
https://read.qxmd.com/read/38514643/vdr-and-deubiquitination-control-neuronal-oxidative-stress-and-microglial-inflammation-in-parkinson-s-disease
#30
JOURNAL ARTICLE
Zihui Zheng, Miao Chen, Shengliang Feng, Huanhuan Zhao, Tiange Qu, Xudong Zhao, Qinli Ruan, Lei Li, Jun Guo
Close correlation between vitamin D (VitD) deficiency and Parkinson's Disease (PD) risk, VitD as an adjuvant treatment promising to improve PD progression. However, VitD excessive intake could induce hypercalcemia and renal damage. Therefore, upregulation of vitD receptor (VDR) is considered a compensatory strategy to overcome VitD insufficiency and alleviate PD symptoms. In this study, we discovered that VDR played antioxidative roles in dopaminergic neurons by decreasing reactive oxygen species (ROS) and maintaining mitochondrial membrane potential...
March 21, 2024: Cell Death Discovery
https://read.qxmd.com/read/38513596/artificial-intelligence-driven-drug-repositioning-uncovers-efavirenz-as-a-modulator-of-%C3%AE-synuclein-propagation-implications-in-parkinson-s-disease
#31
JOURNAL ARTICLE
Jae-Bong Kim, Soo-Jeong Kim, Minyoung So, Dong-Kyu Kim, Hye Rin Noh, Beom Jin Kim, Yu Ree Choi, Doyoon Kim, Heejung Koo, Taeyong Kim, Hyun Goo Woo, Sang Myun Park
Parkinson's disease (PD) is a complex neurodegenerative disorder with an unclear etiology. Despite significant research efforts, developing disease-modifying treatments for PD remains a major unmet medical need. Notably, drug repositioning is becoming an increasingly attractive direction in drug discovery, and computational approaches offer a relatively quick and resource-saving method for identifying testable hypotheses that promote drug repositioning. We used an artificial intelligence (AI)-based drug repositioning strategy to screen an extensive compound library and identify potential therapeutic agents for PD...
March 20, 2024: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/38513594/tolperisone-hydrochloride-improves-motor-functions-in-parkinson-s-disease-via-mmp-9-inhibition-and-by-downregulating-p38-mapk-and-erk1-2-signaling-cascade
#32
JOURNAL ARTICLE
Bushra Zaman, Irona Mostafa, Tazree Hassan, Shamim Ahmed, Nusrat Jahan Ikbal Esha, Fowzia Afsana Chowdhury, Tory Bosu, Humayra Noor Chowdhury, Anup Mallick, Mm Shanjid Islam, Ayesha Sharmin, Kabir M Uddin, Md Mainul Hossain, Mahbubur Rahman
The mitogen-activated protein kinase (MAPK) signaling pathway, particularly the p38 MAPK and ERK1/2, has been implicated in the pathogenesis of Parkinson's disease (PD). Recent studies have shown that MAPK signaling pathway can influence the expression of matrix metalloproteinase 9 (MMP-9), known for its involvement in various physiological and pathological processes, including neurodegenerative diseases. This study explores the modulation of MMP-9 expression via the MAPK/ERK signaling cascade and its potential therapeutic implications in the context of PD-associated motor dysfunction...
March 20, 2024: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/38513164/bridging-the-gap-local-field-potentials-offer-a-peek-into-the-brain-of-a-person-with-parkinson-disease
#33
JOURNAL ARTICLE
Gregory Brown, Sol De Jesus
Clinically available deep brain recordings in patients with Parkinson disease (PD) offer insights into disease mechanisms and create a pathway for personalized treatment strategies. This case illustrates the transformative potential of recordings of neuronal firing in the form of local field potentials (LFPs) by detailing a patient's clinical trajectory for 6 months after deep brain stimulation (DBS) surgery to treat their PD symptoms. LFPs, obtained easily in clinic with a tablet interface to measure and track brain rhythms across the disease course, enriched the patient's clinical picture...
April 23, 2024: Neurology
https://read.qxmd.com/read/38513154/bv2-membrane-coated-pegylated-liposomes-delivered-hfgf21-to-cortical-and-hippocampal-microglia-for-alzheimer-s-disease-therapy
#34
JOURNAL ARTICLE
Heng-Cai Wang, Wei Yang, Ling Xu, Yong-Hui Han, Yi Lin, Cui-Tao Lu, Kwonseop Kim, Ying-Zheng Zhao, Xi-Chong Yu
Microglia-mediated inflammation is involved in the pathogenesis of Alzheimer's disease (AD), whereas hFGF21 has demonstrated the ability to regulate microglia activation in Parkinson's disease, indicating a potential therapeutic role in AD. However, challenges such as aggregation, rapid inactivation, and the blood-brain barrier hinder its effectiveness in treating AD. This study develops targeted delivery of hFGF21 to activated microglia using BV2 membrane-coated PEGylated liposomes (hFGF21@BCM-LIP), preserving the bioactivity of hFGF21...
March 21, 2024: Advanced Healthcare Materials
https://read.qxmd.com/read/38513128/%C3%A2-notas-la-diferencia-do-you-hear-the-difference-perceptual-consequences-of-intensive-voice-treatment-in-spanish-speakers-with-parkinson-s-disease
#35
JOURNAL ARTICLE
Gemma Moya-Galé, Jonathan Delgado Hernández, Alireza Goudarzi, Stephen J Walsh
PURPOSE: The primary objective of this study was to explore the effects of intensive voice-focused treatment on speech parameters in Spanish speakers with dysarthria associated with Parkinson's disease (PD) as perceived by naïve listeners. METHOD: Fifteen Spanish speakers with dysarthria associated with PD received the Lee Silverman Voice Treatment (LSVT LOUD) for a month. Voice and speech recordings were conducted pretreatment, posttreatment, and at a 1-month follow-up...
March 21, 2024: Journal of Speech, Language, and Hearing Research: JSLHR
https://read.qxmd.com/read/38512013/clinical-insights-into-the-use-of-speech-amplification-devices-for-managing-hypophonia-interviews-with-speech-language-pathologists
#36
JOURNAL ARTICLE
Kelly Gates, Thea Knowles, Helen Mach, Jeff Higginbotham
PURPOSE: The purpose of this qualitative interview study was to identify themes regarding considerations in the usage of speech amplification device usage for people with Parkinson's disease (PD) and hypophonia from the perspective of speech-language pathologists (SLPs). METHOD: Eligible participants included SLPs currently practicing in the United States or Canada with experience working with clients with PD for at least 2 years. Ten SLPs participated in 60-min interviews conducted via Zoom...
March 21, 2024: American Journal of Speech-language Pathology
https://read.qxmd.com/read/38509878/integrated-network-pharmacology-and-phosphoproteomic-analyses-of-baichanting-in-parkinson-s-disease-model-mice
#37
JOURNAL ARTICLE
Xin Gao, Jiaqi Fu, DongHua Yu, Fang Lu, Shumin Liu
The incidence rate of Parkinson's disease (PD) is increasing yearly. Neuronal apoptosis caused by abnormal protein phosphorylation is closely related to the pathogenesis of Parkinson's disease. At present, few PD-specific apoptosis pathways have been revealed. To investigate the effect of Baichanting (BCT) on apoptosis from the perspective of protein phosphorylation, α-syn transgenic mice were selected to observe the behavioral changes of the mice, and the apoptosis of substantia nigra cells were detected by the HE method and TUNEL method...
March 30, 2024: Heliyon
https://read.qxmd.com/read/38509589/transcranial-alternating-current-stimulation-improves-quality-of-life-in-parkinson-s-disease-study-protocol-for-a-randomized-double-blind-controlled-trial
#38
JOURNAL ARTICLE
Hong-Yu Zhang, Ting-Ting Hou, Zhao-Hui Jin, Tian Zhang, Yi-Heng Wang, Zi-Hao Cheng, Yong-Hong Liu, Jin-Ping Fang, Hong-Jiao Yan, Yi Zhen, Xia An, Jia Du, Ke-Ke Chen, Zhen-Zhen Li, Qing Li, Qi-Ping Wen, Bo-Yan Fang
BACKGROUND: The neural cells in the brains of patients with Parkinson's disease (PWP) display aberrant synchronized oscillatory activity within the beta frequency range. Additionally, enhanced gamma oscillations may serve as a compensatory mechanism for motor inhibition mediated by beta activity and also reinstate plasticity in the primary motor cortex affected by Parkinson's disease. Transcranial alternating current stimulation (tACS) can synchronize endogenous oscillations with exogenous rhythms, thereby modulating cortical activity...
March 20, 2024: Trials
https://read.qxmd.com/read/38509320/revolutionizing-brain-interventions-the-multifaceted-potential-of-histotripsy
#39
REVIEW
Yash Verma, Arosh S Perera Molligoda Arachchige
Histotripsy, a non-thermal ultrasound technique, holds significant promise in various applications within the realm of brain interventions. While its use for treating brain tumors is somewhat limited, focused ultrasound technology has been extensively investigated for a wide range of purposes within the brain, including disrupting the blood-brain barrier, supporting immunotherapy, addressing conditions like essential tremor, Parkinson's disease, Alzheimer's disease, epilepsy, and neuropathic pain. Research findings indicate that histotripsy can reduce tumor cells with fewer pulses, minimizing the risk of bleeding and cellular injury...
March 21, 2024: Neurosurgical Review
https://read.qxmd.com/read/38508469/consistent-abnormal-activity-in-the-putamen-by-dopamine-modulation-in-parkinson-s-disease-a-resting-state-neuroimaging-meta-analysis
#40
REVIEW
Danyan Rong, Chuan-Peng Hu, Jiaying Yang, Zhiying Guo, Weiguo Liu, Miao Yu
OBJECTIVE: This study aimed to elucidate brain areas mediated by oral anti-parkinsonian medicine that consistently show abnormal resting-state activation in PD and to reveal their functional connectivity profiles using meta-analytic approaches. METHODS: Searches of the PubMed, Web of Science databases identified 78 neuroimaging studies including PD OFF state (PD-OFF) versus (vs.) PD ON state (PD-ON) or PD-ON versus healthy controls (HCs) or PD-OFF versus HCs data...
March 18, 2024: Brain Research Bulletin
keyword
keyword
158576
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.